Regranex

RSS

Withdrawn

This medicine's authorisation has been withdrawn

becaplermin
MedicineHumanWithdrawn

Irish is available via eTranslation, the European Commission's machine translation service.

Translate to Irish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On the 29 March 1999 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Regranex (becaplermin), which had been approved, in association with other good wound care measures, to promote granulation and thereby the healing of full-thickness, neuropathic, chronic, diabetic ulcers less than or equal to 5 cm2 . The marketing authorisation holder (MAH) responsible for Regranex was Janssen-Cilag International NV. 

The European Commission was notified by a letter dated 20 June 2012 of the MAH’s decision to voluntarily withdraw the marketing authorisation as of the Commission Decision date for Regranex for commercial reasons. Regranex was marketed in France, Ireland, Germany, Netherlands, Sweden, Spain and UK. 

On 16 July 2012 the European Commission issued a decision to withdraw the marketing authorisation for Regranex. Pursuant to this decision the European Public Assessment Report for Regranex is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (447.48 KB - PDF)

Amharc

español (ES) (354.04 KB - PDF)

Amharc

čeština (CS) (414.18 KB - PDF)

Amharc

dansk (DA) (356.19 KB - PDF)

Amharc

Deutsch (DE) (357.22 KB - PDF)

Amharc

eesti (ET) (349.88 KB - PDF)

Amharc

ελληνικά (EL) (454.3 KB - PDF)

Amharc

français (FR) (357.92 KB - PDF)

Amharc

italiano (IT) (357.49 KB - PDF)

Amharc

latviešu (LV) (406.12 KB - PDF)

Amharc

lietuvių (LT) (384.62 KB - PDF)

Amharc

magyar (HU) (407.98 KB - PDF)

Amharc

Malti (MT) (412.32 KB - PDF)

Amharc

Nederlands (NL) (354.56 KB - PDF)

Amharc

polski (PL) (414.94 KB - PDF)

Amharc

português (PT) (356.79 KB - PDF)

Amharc

română (RO) (382.94 KB - PDF)

Amharc

slovenčina (SK) (412.74 KB - PDF)

Amharc

slovenščina (SL) (407.06 KB - PDF)

Amharc

suomi (FI) (356.51 KB - PDF)

Amharc

svenska (SV) (349.38 KB - PDF)

Amharc

Product information

български (BG) (854.61 KB - PDF)

Amharc

español (ES) (429.44 KB - PDF)

Amharc

čeština (CS) (646.87 KB - PDF)

Amharc

dansk (DA) (429.78 KB - PDF)

Amharc

Deutsch (DE) (437.03 KB - PDF)

Amharc

eesti (ET) (707.14 KB - PDF)

Amharc

ελληνικά (EL) (886.04 KB - PDF)

Amharc

français (FR) (497.39 KB - PDF)

Amharc

italiano (IT) (435.31 KB - PDF)

Amharc

latviešu (LV) (1.14 MB - PDF)

Amharc

lietuvių (LT) (751.74 KB - PDF)

Amharc

magyar (HU) (640.61 KB - PDF)

Amharc

Malti (MT) (1.18 MB - PDF)

Amharc

Nederlands (NL) (703.73 KB - PDF)

Amharc

polski (PL) (1.16 MB - PDF)

Amharc

português (PT) (706.88 KB - PDF)

Amharc

română (RO) (775.15 KB - PDF)

Amharc

slovenčina (SK) (1.09 MB - PDF)

Amharc

slovenščina (SL) (1.1 MB - PDF)

Amharc

suomi (FI) (427.23 KB - PDF)

Amharc

svenska (SV) (419.11 KB - PDF)

Amharc

Íslenska (IS) (708.77 KB - PDF)

Amharc

norsk (NO) (713.55 KB - PDF)

Amharc
Latest procedure affecting product information:IB/0037/G
11/10/2010
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (326.45 KB - PDF)

Amharc

español (ES) (268.13 KB - PDF)

Amharc

čeština (CS) (264.2 KB - PDF)

Amharc

dansk (DA) (280.29 KB - PDF)

Amharc

Deutsch (DE) (272.38 KB - PDF)

Amharc

eesti (ET) (227.33 KB - PDF)

Amharc

ελληνικά (EL) (301.85 KB - PDF)

Amharc

français (FR) (269.77 KB - PDF)

Amharc

italiano (IT) (224.88 KB - PDF)

Amharc

latviešu (LV) (315.18 KB - PDF)

Amharc

lietuvių (LT) (291.46 KB - PDF)

Amharc

magyar (HU) (297.51 KB - PDF)

Amharc

Malti (MT) (310.49 KB - PDF)

Amharc

Nederlands (NL) (268.8 KB - PDF)

Amharc

polski (PL) (311.87 KB - PDF)

Amharc

português (PT) (268.12 KB - PDF)

Amharc

română (RO) (289.17 KB - PDF)

Amharc

slovenčina (SK) (264.71 KB - PDF)

Amharc

slovenščina (SL) (266.54 KB - PDF)

Amharc

suomi (FI) (268.3 KB - PDF)

Amharc

svenska (SV) (269.98 KB - PDF)

Amharc

Product details

Name of medicine
Regranex
Active substance
becaplermin
International non-proprietary name (INN) or common name
becaplermin
Therapeutic area (MeSH)
  • Wound Healing
  • Skin Ulcer
Anatomical therapeutic chemical (ATC) code
D03AX06

Pharmacotherapeutic group

Preparations for treatment of wounds and ulcers

Therapeutic indication

Regranex is indicated, in association with other good wound care measures, to promote granulation and thereby the healing of full-thickness, neuropathic, chronic, diabetic ulcers less than or equal to 5 cm2.

Authorisation details

EMA product number
EMEA/H/C/000212
Marketing authorisation holder
Janssen-Cilag International NV

Turnhoutseweg, 30
B-2340 Beerse
Belgium

Marketing authorisation issued
29/03/1999
Withdrawal of marketing authorisation
16/07/2012
Revision
18

Assessment history

This page was last updated on

Share this page